FDA Clears New Mechanical Blood Clot Removal System For Coronary & Peripheral Vasculature

PARK CITY, UTAH – Control Medical Technology, Park City, Utah, announced the FDA cleared, and the company began shipping, the new ASPIRE RX-LP6 Rapid-Exchange Mechanical Thrombectomy System™ to remove fresh blood clots and emboli from coronary and peripheral vasculature.

Blood clot removal, or thrombectomy, is performed throughout the body. The procedure typically involves introducing a small catheter into a patient’s leg, advancing the catheter tip to the target organ / blood clot, and creating aspiration force with a basic syringe or electromechanical pump.

“Blood clots are not homogenous and clinicians need a tool box of solutions to meet patient needs,” said Shawn Fojtik, President of Control Medical Technology. “The ASPIRE RX-LP6 System is an important step forward to improve thrombectomy speed, control, volume, and performance.”

When removing blood clots, sometimes subtle low thrombectomy force is needed, other times continuous, increased, and/or pulsed force is required. Basic syringes-based thrombectomy devices lack this versatility and many clinicians complain when syringes loose aspiration force as their barrels start to fill with fluid.

In addition, basic syringes typically aspirate only 30ml at a time requiring the clinician to repeatedly connect, disconnect, and re-connect syringes. This sequence is slow, inefficient, prone to complications, and can increase staff biohazard risk.

Electromechanical pumps can create pulsed and/or continuous aspiration force, but can be complex, require the hospital to purchase expensive capital equipment, commit to service contracts, and cost significantly more per-patient than basic syringe systems.

“ASPIRE technology allows users to instantly start, stop, increase, decrease, maintain, and/or pulse thrombectomy force with a simple user interface and no capital equipment,” continued Fojtik. “The ASPIRE system has been used as a primary thrombectomy tool and in situations where syringe based devices fail. We feel privileged to play a role in improve patient care during a wide range of procedures and look forward to adding more catheters to the line.”

Control Medical Technology’s ASPIRE Mechanical Thrombectomy System is now one of the largest FDA cleared platforms in the United States with over-the-wire and rapid-exchange catheters powered by a novel mechanical thrombectomy driver/pump. The platform is protected by 10+ issued and pending patents.

For more information about Control Medical, call 1-954-534-9345 or visit www.CONTROLMEDTECH.com, Park City, Utah.

Media Contact: Chris Livingstone

Chris@aspirationmedical.com